SPOTLIGHT -
1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)
28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies
31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy
48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study
53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)
55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)
54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)
Metastatic Triple-Negative Breast Cancer: Unmet Needs and Future Directions in Care
Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.
Interpreting Data From ASCENT: Practical Use of Sacituzumab Govitecan in mTNBC
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Sacituzumab Govitecan in mTNBC: Results From the ASCENT Study
Metastatic Triple-Negative Breast Cancer: An Evolving Treatment Landscape
Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.
Circulating Tumor DNA: Future Directions in Care
Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.
Considering Real-World Applications With ctDNA
Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.
Impact of ctDNA on the Management of Breast Cancer
Focusing broadly on breast cancer, expert oncologists detail how ctDNA may impact patient monitoring and treatment decisions moving forward.
Scenario 2: Use of ctDNA to Monitor High-Risk TNBC
Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.
Nuancing the Benefit of Circulating Tumor DNA
In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.
Clinical Trial Data on Use of ctDNA Assays
Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.
Identifying Use of ctDNA Across Tumor Types
Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.
Understanding the Mechanisms and Use of ctDNA and MRD Testing
Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.
Future Role of ctDNA in CRC: Surveillance and Treatment Selection
Shared insight on the potential roles of ctDNA and MRD testing in the monitoring and treatment of patients with colorectal cancer.
Scenario 1: ctDNA to Determine Use of Adjuvant Chemotherapy in Stage II CRC
Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.
Next-Gen SERDs in ER+/HER- Breast Cancer Satellite Symposium
Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.
Recap Evolving HER2+ Metastatic Breast Cancer Landscape
Experts discussed the changing landscape in treatments for HER2-positive metastatic breast cancer.
Reflections on Future Treatment Strategies for HER2+ mBC
Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.
Patient Case #3: Sequencing Therapy and Monitoring Results
Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.
Audience Questions on Selecting Optimal Therapy for mBC
Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.
